Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 
1664 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sarcoma
2017-004761-28: A study of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal tumors (GISTs) Estudio de Selinexor en combinación con imatinib en pacientes con tumores gastrointestinales (GISTs) metastasicos o irresecables

Not yet recruiting
1/2
41
Europe
Selinexor, Glivec, KTP-330, STI571, Coated tablet, Tablet, Glivec
Grupo Español de Investigación en Sarcomas, Karyopharm
Gastrointestinal stromal tumor (GIST) Tumor del estroma gastrointestinal, Gastrointestinal stromal tumor (GIST) is a rare cancer affecting the digestive tract or nearby structures within the abdomen. Tumor del estroma gastrointestinal es un cancer raro que afecta el tracto digestivo y otras estructuras adyacentes en el abdomen, Diseases [C] - Cancer [C04]
 
 
2019-000987-80: A multicentre trial evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma Etude multicentrique, menée en ouvert, de Phase I/II visant à évaluer la combinaison d’un inhibiteur de MEK et d’un anti-PDL1 chez des patients pédiatriques et adultes présentant un sarcome des tissus mous de stade avancé ou métastatique

Not yet recruiting
1/2
80
Europe
atezolizumab, cobimetinib, R05541267, R05514041, RO5514041/F12, Concentrate for solution for infusion, Film-coated tablet, Powder for oral solution, TECENTRIQ, COTELLIC
Centre Léon Bérard, INCA
advanced/metastatic soft tissu sarcoma sarcomes des tissus mous de stade avancé/métastatique, soft tissu sarcoma sarcomes des tissus mous, Diseases [C] - Cancer [C04]
 
 
2018-003120-36: An open-label study in patients with advanced cancer

Not yet recruiting
1/2
174
Europe
IMC-C103C, Atezolizumab, IMC-C103C, 1380723-44, Concentrate for solution for infusion, Tecentriq
Immunocore Limited, Immunocore Limited
Patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, urothelial carcinoma, ovarian carcinoma and synovial sarcoma, Patients with advanced non-small cell lung cancer, head and neck cancer, esophageal cancer, gastric, bladder cancer (also called urothelial cancer), ovarian cancer and synovial sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT03250325: Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma

Hourglass Jan 2020 - Jan 2020 : P1/2 trial in unresectable progressive/recurrent synovial sarcoma
Completed
1/2
8
Japan
TBI-1301, Cyclophosphamide
Takara Bio Inc.
Synovial Sarcoma
01/20
03/22
NCT03676985: A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Recruiting
1/2
15
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Osteosarcoma
02/20
06/23
TARMIC, NCT02805725: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

Completed
1/2
50
Europe
Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide, Phase 2: Cyclophosphamide
Institut Bergonié, PharmaMar
Soft-tissue Sarcomas
04/20
12/21
CS3007-101, NCT04254939: A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Checkmark Preliminary results from a bridging study in Chinese Patients with Unresectable or Metastatic GIST
Sep 2020 - Sep 2020: Preliminary results from a bridging study in Chinese Patients with Unresectable or Metastatic GIST
Checkmark Partial results from P1/2 bridging study in Chinese patients with unresectable or metastatic GIST at ASCO 2020
May 2020 - May 2020: Partial results from P1/2 bridging study in Chinese patients with unresectable or metastatic GIST at ASCO 2020
Completed
1/2
65
RoW
CS3007 (BLU-285)
CStone Pharmaceuticals, Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors
04/20
04/23
2020-000505-80: A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer. Etude clinique de Phase I/IIa évaluant BT-001 chez des patients présentant des tumeurs solides avancées ou métastatiques.

Not yet recruiting
1/2
258
Europe
Pembrolizumab, BT-001, Solution for injection, Powder for concentrate for solution for infusion, Keytruda (pembrolizumab)
TRANSGENE, TRANSGENE, BioInvent International AB (publ)
Phase I: Advanced or metastatic Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase I: Tumeurs solides avancées ou métastatiques incluant les sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellulesPhase IIa: Sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellules, Advanced or metastatic solid tumors Tumeurs solides avancées ou métastatiques, Diseases [C] - Cancer [C04]
 
 
NCT02095132: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Completed
1/2
76
Canada, US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E
National Cancer Institute (NCI)
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Pineoblastoma, Primary Central Nervous System Neoplasm, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
12/20
06/23
NCT03320330: Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Active, not recruiting
1/2
26
US
Laboratory Biomarker Analysis, Pepinemab, moAb VX15/2503, VX15/2503, Pharmacological Study
Children's Oncology Group, National Cancer Institute (NCI)
Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma
12/20
09/24
NCT02650986: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Active, not recruiting
1/2
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Laboratory Biomarker Analysis, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes, TGFbDNRII-transduced Autologous TILs
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
03/21
07/32
LEADER, NCT03526679: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

Active, not recruiting
1/2
30
RoW
Eribulin, Halaven, Lenvatinib, Lenvima
National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan
Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer
06/21
06/23
NCT03205644: VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Not yet recruiting
1/2
75
US
Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Laboratory Biomarker Analysis, Pharmacological Study
Children's Oncology Group, National Cancer Institute (NCI), COG Phase I Consortium
Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm
09/21
10/21
NCT02304458 / 2014-005674-11: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Completed
1/2
140
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
09/21
03/23
2021-001186-20: Trial of different schemes of PM14 alone and in combination with radiotherapy in soft tissue sarcomas and other solid tumors Ensayo de diferentes esquemas de PM14 solo y en combinación con radioterapia en sarcomas de tejidos blandos y otros tumores sólidos.

Not yet recruiting
1/2
195
Europe
PM14, Lyophilisate for solution for infusion
GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS, GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS
Advanced soft tissue sarcoma and other solid tumors Sarcoma de tejidos blandos avanzado y otros tumores sólidos, Soft tissue tumors Tumores en tejidos blandos, Diseases [C] - Cancer [C04]
 
 
TQBSP, NCT04690725: TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss

Active, not recruiting
1/2
29
RoW
TQB3525
Peking University People's Hospital
Safety Issues, Efficacy, Self
01/22
06/22
NCT03602833: Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma

Active, not recruiting
1/2
12
Europe
Compound 451238
Royal Marsden NHS Foundation Trust, Merck KGaA, Darmstadt, Germany
Soft-tissue Sarcoma
05/22
01/23
NCT03508726: High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Completed
1/2
25
US
Ascorbate, Ascorbic Acid, Vitamin C, Pharmacological ascorbate
Mohammed Milhem, University of Iowa
Soft Tissue Sarcoma
06/22
06/24
2021-003762-13: PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH PULMONARY METASTASES (ANNA-SARC)

Not yet recruiting
1/2
30
Europe
L-Annamycin, CP-507, Lyophilisate for solution for infusion
Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie – Państwowy Instytut Badawczy (NIO-PIB), Agencja Badan Medycznych, Moleculin Biotech
soft tissue sarcomas, soft tissue sarcomas, Diseases [C] - Cancer [C04]
 
 
NCT03345485: Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

Completed
1/2
71
Canada, US
Tinostamustine (EDO-S101)
Mundipharma Research Limited
Small-cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
07/22
03/23
NCT03802071: A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

Active, not recruiting
1/2
44
RoW
Durvalumab+doxorubicin cobination
Yonsei University
Sarcoma
08/22
08/22
2019-003034-16: Trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ensayo de LB-100 más doxorrubicina vs. doxorrubicina sola en primera lnea de sarcomas de tejidos blandos avanzados

Not yet recruiting
1/2
152
Europe
Doxorubicin, LB-100, Solution for infusion, Solution for injection, Doxorubicina Accord
Grupo Español de Investigación en Sarcomas (GEIS), Lixte Biotechnology Holdings, Inc.
Advanced/metastatic soft tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxoid and hypercellular myxoid liposarcoma, myxofibrosarcoma, NOS sarcoma, synovial sarcoma, fibrosarcoma, or malignant nerve sheath tumor) Sarcoma de tejidos blandos avanzado/metastásico (sarcoma pleomórfico indiferenciado, leiomiosarcoma, liposarcoma mixoide y liposarcoma hipercelular mixoide, mixofibrosarcoma, sarcomas no especificados en otra categoría, sarcoma sinovial, fibrosarcoma o tumor maligno de la vaina del nervio periférico), Advanced/metastatic soft tissue sarcoma Sarcoma de tejidos blandos avanzado/metastásico, Diseases [C] - Cancer [C04]
 
 
2021-005617-14: Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II) Estudio para evaluar la seguridad e identificar la dosis de ribociclib en combinación con temozolomida y topotecán (TOTEM) en pacientes (12 meses - 21 años) con tumores sólidos recidivantes o refractarios (Fase I) y evaluar la eficacia y seguridad en pacientes (12 meses - 21 años) con neuroblastoma recidivante o refractario (Fase II)

Ongoing
1/2
230
Europe, RoW
ribociclib, temozolomida 5 mg cápsulas duras, topotecan, temozolomida 20 mg cápsulas duras, temozolomida 100 mg cápsulas duras, temozolomida 140 mg cápsulas duras, temozolomida 180 mg cápsulas duras, temozolomida 250 mg cápsulas duras, LEE011, Powder for oral solution, Capsule, hard, Concentrate for solution for infusion, Temozolomid SUN & Temozolomid Accord, Potactasol & Hycamtin
Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG
relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years old neuroblastoma recidivante o refractario y otros tumores sólidos (incluyendo meduloblastoma, glioma de alto grado, tumores rabdoides malignos y rabdomiosarcoma) en pacientes con edades comprendidas entre los 12 meses y los 21 años, Recurrent solid tumors in patients from 12 months to 21 years old Tumores sólidos recurrentes en pacientes con edades comprendidas entre los 12 meses y los 21 años, Diseases [C] - Cancer [C04]
 
 
NCT04260802: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Recruiting
1/2
116
Canada
OC-001, Drug: OC-001 in Combination with Avelumab
Ocellaris Pharma, Inc.
Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer
03/26
09/26
NCT03422679 / 2017-001491-35: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Terminated
1/2
79
Europe, US, RoW
CB-103
Cellestia Biotech AG
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
11/22
11/22
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Active, not recruiting
1/2
19
US
Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient
University of Washington, Aadi Bioscience, Inc.
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
11/22
02/25
2021-005086-41: Cell therapy clinical trial of BOXR1030 in GPC3 positive liver, squamous lung, Merkel cell cancer, and myxoid/round cell liposarcoma

Not yet recruiting
1/2
98
Europe
BOXR1030, Dispersion for infusion
SOTIO Biotech Inc, SOTIO Biotech a.s.
Histologically confirmed advanced unresectable or metastatic hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC) of the lung, myxoid/round cell liposarcoma, or Merkel cell carcinoma (MCC) with GPC3 overexpression by IHC, with a cytoplasmic/membranous H-score >30 for study eligibility. In the event of a tumor agnostic expansion cohort, other indications may be investigated., Patients with advanced, unresectable liver, squamous lung, and Merkel cell cancer, and myxoid/round cell liposarcoma that have tumor that is positive for GPC3 protein, Diseases [C] - Cancer [C04]
 
 
NCT03458728 / 2017-000383-15: Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Terminated
1/2
31
US
Copanlisib (BAY806946)
Bayer, Bayer AG
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma
02/23
02/23
GEMMK, NCT03123276: Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

Active, not recruiting
1/2
24
Europe
Pembrolizumab, Keytruda, Gemcitabine
Royal Marsden NHS Foundation Trust, Merck Sharp & Dohme LLC
Sarcoma
02/23
02/23
NCT04599062: TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Active, not recruiting
1/2
8
US
Talimogene Laherparepvec, Radiotherapy
Mohammed Milhem, Amgen
Soft Tissue Sarcoma
02/23
11/24
KEYNOTE-A10, NCT03058289: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Checkmark Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Nov 2021 - Nov 2021: Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Completed
1/2
110
Canada, US
INT230-6, anti-PD-1 antibody, pembrolizumab, Keytruda, MK-3475, anti-CTLA-4 antibody, ipilimumab, Yervoy, BMS-734016
Intensity Therapeutics, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
02/23
02/23
ChiCTR2100049548: Open phase I / IIA trial of vg161 monotherapy or combined with apatinib in the treatment of advanced osteosarcoma, Ewing's sarcoma, chordoma and chondrosarcoma

Not yet recruiting
1/2
32
 
VG161 ;VG161+apatinib
Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, No
Advanced osteosarcoma, Ewing's sarcoma, chordoma and chondrosarcoma
 
 
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Recruiting
1/2
73
RoW
CAR-T cell immunotherapy
Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University
B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma
03/23
03/23
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
2020-004246-11: This study will evaluate the safety, tolerability and efficacy of Tinostamustine in late-stage cancer patients. Different types of solid tumors will be treated with Tinostamustine. The study will be performed in multiple centers and countries.

Not yet recruiting
1/2
70
Europe
Tinostamustine, EDO-S101, Lyophilisate for solution for infusion
Mundipharma Research Limited, MUNDIPHARMA RESEARCH LIMITED, Mundipharma Research Limited
• Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refractory ovarian cancer • Cohort 5: Relapsed/refractory endometrial cancer On 05 March 2021 the Sponsor has taken the decision to halt recruitment into the Cohorts for relapsed/refractory triple-negative breast cancer (TNBC) and relapsed/refractory endometrial cancer on this study., "Relapse" means when a few of the original cancer cells survived the initial treatment. "Refractory" is a cancer that may be resistant at the beginning/becomes resistant during treatment., Diseases [C] - Cancer [C04]
 
 
SeliGIST, NCT04138381: Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Active, not recruiting
1/2
30
Europe
Selinexor, Drug Combination, Single agent, Imatinib
Grupo Espanol de Investigacion en Sarcomas
Maximum Tolerated Dose, GIST, Metastatic Adult Soft Tissue Sarcoma, Drug Toxicity, Drug Use
04/23
04/23
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24
NCT04433221: Combination Immunotherapy Targeting Sarcomas

Recruiting
1/2
20
RoW
Multiple sarcoma-specific CAR-T cells and sarcoma vaccines
Shenzhen Geno-Immune Medical Institute, The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen Children's Hospital
Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
05/23
12/23
NCT03338959: Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma

Completed
1/2
27
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, NOS, Energy Type
Fred Hutchinson Cancer Center, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
06/23
08/23
SAKK 66/17, NCT03972436: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Not yet recruiting
1/2
39
Europe
IP-001, Thermal Ablation, TRANBERG Thermal Therapy System®, ®- Thermal Therapy System (Clinical Laserthermia System AB)
Swiss Group for Clinical Cancer Research
Advanced Solid Tumors
06/23
12/23
NCT02584647: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Active, not recruiting
1/2
43
US
PLX3397, No other name, Sirolimus, Rapamune
Gulam Manji, Daiichi Sankyo
Sarcoma, Malignant Peripheral Nerve Sheath Tumors
07/23
06/24
NCT05602792: A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Recruiting
1/2
233
RoW
T3011
ImmVira Pharma Co. Ltd
Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer, Esophagus Cancer, NSCLC, Non-melanoma Skin Cancer
07/23
01/24
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed
1/2
13
US
Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine
Hutchmed, HUTCHMED Limited
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
04/23
04/23
ZN-c3-003, NCT04833582 / 2021-000021-27: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Active, not recruiting
1/2
84
Europe, US
ZN-c3, Gemcitabine, Gemzar
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osteosarcoma
08/23
12/23
TQB2858-I-05, NCT05154630: Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

Terminated
1/2
8
RoW
TQB2858 injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer, Advanced Soft-tissue Sarcoma
03/23
06/23
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
NCT01991379: MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Checkmark Of binimetinib in combination with imatinib for gastrointestinal stromal tumors at ASCO 2015
May 2015 - Jun 2015: Of binimetinib in combination with imatinib for gastrointestinal stromal tumors at ASCO 2015
Checkmark Of binimetinib in combination with imatinib for gastrointestinal stromal tumors at ASCO 2015
May 2015 - May 2015: Of binimetinib in combination with imatinib for gastrointestinal stromal tumors at ASCO 2015
Active, not recruiting
1/2
75
US
MEK162, Imatinib Mesylate (Gleevec®; STI571; NSC #716051), Blood draws, biopsy
Memorial Sloan Kettering Cancer Center
Gastrointestinal Stromal Tumor (GIST)
11/24
11/24
PM1183-A-014-15, NCT02611024: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Recruiting
1/2
320
Europe, US
Lurbinectedin, PM01183, Irinotecan
PharmaMar
Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
03/26
03/26
ALMB-0168-CN-101, NCT04886765: A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Not yet recruiting
1/2
238
NA
ALMB-0168
AlaMab Therapeutics (Shanghai) Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Osteosarcoma
11/23
05/24
NCT05448820: YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Active, not recruiting
1/2
15
US
YH001, Envafolimab, KN035, Doxorubicin
Tracon Pharmaceuticals Inc.
Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
11/23
09/25
Enhancer, NCT05809830: Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

Recruiting
1/2
152
Europe
LB-100 plus Doxorrubicin, Doxorubicin
Grupo Espanol de Investigacion en Sarcomas
Advanced Soft-tissue Sarcoma
06/25
05/26
NCT03356782: Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Recruiting
1/2
20
RoW
Sarcoma-specific CAR-T cells
Shenzhen Geno-Immune Medical Institute
Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
11/23
12/23
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
224
US, RoW
APG-115+Pembrolizumab, Keytruda
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, MPNST, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors
12/24
03/25
SAINT, NCT03138161: Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma

Recruiting
1/2
45
US
Trabectedin, Yondelis, Ipilimumab, Yervoy, Nivolumab, Opdivo
Sarcoma Oncology Research Center, LLC, Bristol-Myers Squibb
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
12/24
03/25
NCT04165330: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruiting
1/2
56
US
AL3818, Anlotinib hydrochloride, Nivolumab Injection, Opdivo
Sarcoma Oncology Research Center, LLC, Advenchen Laboratories, LLC
Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
12/24
03/25
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT04220229: Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Active, not recruiting
1/2
6
US
Cabozantinib S-malate, 1140909-48-3, BMS-907351, Butanedioic acid, Cabometyx, Cometriq, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
University of Washington, Exelixis
Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities
04/24
01/27
IMMCO-1, NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Recruiting
1/2
29
US
Atezolizumab, Tecentriq, Tivozanib, Fotivda
University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
12/24
12/25
NCT04742959: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
203
US
TT-00420, Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
02/24
02/24
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
05/24
09/24
NCT05160168: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Terminated
1/2
32
US
THE-630
Theseus Pharmaceuticals
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
02/24
02/24
NCT05084430: Study of Pembrolizumab and M032 (NSC 733972)

Recruiting
1/2
28
US
M032, Pembrolizumab
University of Alabama at Birmingham
Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
03/27
03/28
NCT06239272: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Recruiting
1/2
139
US
Surgical resection, Proton beam radiation therapy, Pazopanib, VOTRIENT®, Ifosfamide, Ifex, Doxorubicin, Adriamycin®, Rubex®, Selinexor, XPOVIO®
St. Jude Children's Research Hospital
Non-rhabdomyosarcoma, Adipocytic Neoplasm, Liposarcoma
06/34
06/37
NCT01837862: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Recruiting
1/2
36
US
Mebendazole, Vermox, Vincristine, Oncovin, Carboplatin, Paraplatin, Temozolomide, Temodar, Bevacizumab, Avastin, Irinotecan, CPT-11, Camptosar
Julie Krystal, Janssen Pharmaceuticals
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
04/24
04/25
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Recruiting
1/2
95
RoW
APG-115, Toripalimab
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Liposarcoma, Advanced Solid Tumor
04/26
01/27
NCT06327477: Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma

Recruiting
1/2
28
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Resection, Surgical Resection, Spatially-fractionated Radiation Therapy, GRID Therapy, SFRT
Northwestern University, National Cancer Institute (NCI)
Retroperitoneal Sarcoma
07/27
07/28
NCT05094804 / 2022-002234-14: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Recruiting
1/2
172
US
OR2805, Cemiplimab, Libtayo, Docetaxel, Taxotere
OncoResponse, Inc., OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
04/24
08/24
NCT06384248: Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma

Not yet recruiting
1/2
30
NA
LTC004
Letolab
Unresectable or Metastatic Sarcoma
12/25
12/25
NCT04579757: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
135
US
Surufatinib and Tislelizumab _ Part 1, HMPL-012, sulfatinib, BGB-A317, Surufatinib and Tislelizumab _ Part 2
Hutchmed, BeiGene
Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
04/24
06/24
NCT05166577: Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Recruiting
1/2
130
Canada, US, RoW
Nanatinostat, VRx-3996, Valganciclovir, Valcyte, Pembrolizumab, Keytruda
Viracta Therapeutics, Inc.
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
12/24
10/25
INJECTABL-1, NCT05688280: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Recruiting
1/2
44
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
05/24
05/24
PHANTOM, NCT06298916: 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Not yet recruiting
1/2
32
NA
64Cu-LNTH-1363S
Lantheus Medical Imaging
Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
11/25
04/26
NCT06380816: A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Not yet recruiting
1/2
167
Europe
UCB4594
Cancer Research UK, UCB Biopharma SRL
Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms, Carcinoma, Renal Cell (Clear Cell Only), Esophageal Neoplasms, Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors), Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms
11/29
11/29
ChiCTR2100046224: A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients with Osteosarcoma

Recruiting
1/2
166
 
ALMB-0168
The First Affiliated Hospital, Sun Yat-Sen University; AlaMab Therapeutics (Shanghai))Inc., Completely self-financing
Osteosarcoma
 
 
NCT06456892: Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen

Recruiting
1/2
82
RoW
Pucotenlimab
Sun Yat-sen University
Rhabdomyosarcoma, Pediatric Cancer
06/26
12/26
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Active, not recruiting
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
09/24
LIGHTBEAM-U01, NCT06395103: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/)

Recruiting
1/2
90
RoW
Zilovertamab vedotin, MK-2140, VLS-101
Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
03/29
03/29
SARC037, NCT04067115: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

Active, not recruiting
1/2
48
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
06/24
06/24
PEPN2112, NCT05071209: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Active, not recruiting
1/2
23
Canada, US
Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344
National Cancer Institute (NCI)
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
12/24
12/24
KEYNOTE-E67, NCT05708950: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Recruiting
1/2
314
US
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, Keytruda, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Kineta Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
06/24
12/24
NCT05099666: Lurbinectedin + Doxorubicin In Leiomyosarcoma

Recruiting
1/2
62
US
Lurbinectedin, Zepzelca, Doxorubicin, Adriamycin
Massachusetts General Hospital, Jazz Pharmaceuticals
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
07/24
07/25
DUET-1, NCT05120271: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Recruiting
1/2
110
US
CAR-GPC3 T Cells, BOXR1030
Sotio Biotech Inc., SOTIO Biotech AG, SOTIO Biotech a.s.
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
04/26
12/41
NCT06217536: Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas

Not yet recruiting
1/2
70
US
Lurbinectedin, Zepzelca, Radiotherapy, Radiation therapy, Non-investigational surgery
University of California, San Francisco, Jazz Pharmaceuticals
Locally Advanced Soft Tissue Sarcoma
01/26
07/27
NCT06465199: Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Not yet recruiting
1/2
253
NA
Difluoromethylornithine (DFMO), Eflornithine, AMXT-1501 Dicaprate
Milton S. Hershey Medical Center, Aminex Therapeutics, Inc.
Atypical Teratoid/Rhabdoid Tumor, Neuroblastoma Recurrent, Embryonal Tumor With Multilayered Rosettes, DIPG Brain Tumor, Ewing Sarcoma, Osteosarcoma Recurrent
07/32
07/34
NCT03709680 / 2021-003444-25: Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active, not recruiting
1/2
128
Europe, Canada, US, RoW
Palbociclib, Ibrance, Temozolomide, Temodar, Irinotecan, Campto, Topotecan, Hycamtin, Cyclophosphamide, Cytoxan
Pfizer, Children's Oncology Group (COG)
Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
08/24
02/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
IRIS, NCT05839275: The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

Recruiting
1/2
52
RoW
Surufatinib, Sintilimab, Radiotherapy
Fudan University
High-Risk Localized Soft Tissue Sarcoma
07/24
07/29
NCT05494580: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Recruiting
1/2
38
RoW
Pamiparib, Poly (ADP-ribose) polymerase (PARP) inhibitor, Surufatinib, Tyrosine Kinase Inhibitor
Sun Yat-sen University, Hutchmed
Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma, Primary Peritoneal Cancer
08/24
08/25
RAPID, NCT05774275: The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Recruiting
1/2
52
RoW
Pegylated Liposomal Doxorubicin, Doxil, Doxorubicin, Doxorubicin Hydrochloride, Anti-PD-1 monoclonal antibody, Sintilimab, Radiotherapy
Fudan University
High-Risk Localized Soft Tissue Sarcoma
08/24
08/29
LIBRETTO-121, NCT03899792 / 2019-000212-28: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Recruiting
1/2
50
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
12/24
05/29
NCT04095221: A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Active, not recruiting
1/2
21
US
Prexasertib, Irinotecan
Memorial Sloan Kettering Cancer Center
Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
09/24
09/24
SC9/ABX, NCT04528680: Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Recruiting
1/2
57
US
Sonication for opening of blood-brain barrier, SonoCloud-9 device, SC-9, Chemotherapy, albumin-bound paclitaxel, Abraxane®, ABX, Chemotherapy, carboplatin, Paraplatin
Northwestern University, CarThera, Bristol-Myers Squibb, Lantheus Medical Imaging
Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
09/24
09/25
NCT03598595: Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Active, not recruiting
1/2
31
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Hydroxychloroquine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Osteosarcoma, Refractory Osteosarcoma
09/24
09/24
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1/2
50
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
NCT05187338: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Recruiting
1/2
100
RoW
ipilimumab +pembrolizumab +durvalumab
Second Affiliated Hospital of Guangzhou Medical University
Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Sarcoma
10/29
10/35
NCT06393751: Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Not yet recruiting
1/2
127
NA
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Tolinapant, ASTX 660, ASTX660, XIAP/cIAP1 Antagonist ASTX660
National Cancer Institute (NCI)
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Adenocarcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent High Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Adenocarcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
02/28
02/28
NCT03373097 / 2017-002475-26: Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Recruiting
1/2
42
Europe
GD2-CART01
Bambino Gesù Hospital and Research Institute
Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors, Osteosarcoma, Ewing Sarcoma, Sarcoma
12/24
12/27
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
12/24
12/24
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/24
 

Download Options